Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.
about
Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumorsA Bayesian approach for PK/PD modeling with PD data below limit of quantification.Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.The present and future of withdrawal period calculations for milk in the European Union: dealing with data below the limit of quantification.Handling data below the limit of quantification in mixed effect models.Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control studyAxitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Use of pharmacokinetic data below lower limit of quantitation valuesExtension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldPharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disordersPopulation pharmacokinetic analysis of axitinib in healthy volunteers.Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants.Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors.Population-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis.Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites.Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis.Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance.Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail.Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.Association between perfluorinated compounds and time to pregnancy in a prospective cohort of Danish couples attempting to conceive.
P2860
Q28257098-88C49C18-9D1F-475C-B185-11B57E315598Q30573792-A683686E-6434-439E-AEA3-A71A91141C98Q30815467-2061145A-9BF9-421C-9AA1-B5E0FCCCABF6Q31118795-E94064A9-A78D-45BD-87C1-F14E9E867E5AQ33447430-96909E42-28D7-4074-9784-9F46A114C836Q33521471-95F68BA4-E46C-40B1-B41F-A77341DA8C84Q33917058-5934F7F2-316F-4464-AE2D-8EDDBB38C3E7Q34037355-1744A676-0549-44B6-9C73-473997BA25BAQ34053280-AD3D03C9-A5E2-4870-8C1F-174CE2C46EFAQ34245458-A4B9A5BF-9B9F-4B09-BBF1-F7A1074AC3D5Q34315916-64960DAF-1EAD-4C31-8114-6E0B7A15B5D0Q34376951-B7C146F0-66E2-4329-BCC0-BA897F5DD8EAQ34687255-C452EE96-97B4-4669-A7A2-111FD4C335DFQ35176909-AFD54753-7DB9-46C4-8F71-C3D7B3CB0C49Q36102602-CC219AD3-9D9E-498D-A84F-C1F2239A3E6EQ36411982-5594086F-D381-431F-9F6F-41A19A6C0BF4Q36684146-F1C22BB2-8EE8-41FD-9AEB-8ED0695D2C77Q37582146-B1419FAF-A88A-478A-A1A4-2C4B5727FBF0Q37635202-514674C9-D5AA-482A-ACD0-4E0866DA1837Q38695980-E46EBEFE-4C35-44A8-A423-32DE5F0A92B0Q38790656-00756763-E4A1-4FF1-949D-A33C5CE3B5C8Q38844529-3BF42171-02DD-4F03-A0AA-8D4984B3C95AQ41986943-D291EF8E-4AF4-46D7-AA73-B060C35BA393Q43070221-26EC7BA5-D1DC-4DC0-8567-1223B8005F4DQ44108202-D3C7B456-1CC3-419C-8367-B8BA278A04C3Q44474357-1A79D30E-5E54-4B27-8267-199899A47317Q44965471-7C357951-5EF1-4883-8C55-44D493D42E19Q50555508-D81292BB-D6F5-454D-BC28-524FD95F20F3
P2860
Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Impact of omission or replacem ...... es in a two-compartment model.
@ast
Impact of omission or replacem ...... es in a two-compartment model.
@en
type
label
Impact of omission or replacem ...... es in a two-compartment model.
@ast
Impact of omission or replacem ...... es in a two-compartment model.
@en
prefLabel
Impact of omission or replacem ...... es in a two-compartment model.
@ast
Impact of omission or replacem ...... es in a two-compartment model.
@en
P356
P1476
Impact of omission or replacem ...... es in a two-compartment model.
@en
P2093
Mats O Karlsson
Vincent Duval
P304
P356
10.1023/A:1021441407898
P577
2002-12-01T00:00:00Z